Enclomiphene: the fertility-sparing alternative to TRT, explained

What is enclomiphene?

Enclomiphene citrate is one of the two isomers that make up clomiphene, a selective estrogen receptor modulator (SERM) used for decades in fertility medicine. Clomiphene is a mix of two forms: zuclomiphene (long-acting, more estrogenic) and enclomiphene (the anti-estrogenic component that does the useful work in men). Enclomiphene isolates that active half.

Its mechanism is the reverse of testosterone therapy. Normally, estrogen tells the hypothalamus and pituitary to slow down the hormones that drive the testes. Enclomiphene blocks estrogen receptors in the brain, so the "slow down" signal is muted. The pituitary responds by releasing more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which stimulate the testes to produce more of their own testosterone and to keep making sperm. In short: TRT sends testosterone in from outside; enclomiphene turns the body's own production back up.

How is enclomiphene different from TRT?

The two treat the same symptom — low testosterone — by opposite routes, and the trade-offs follow from that difference.

The one-line version: if keeping fertility matters, enclomiphene is the reason to think twice before starting testosterone. If your testes can no longer respond to signaling (primary hypogonadism), enclomiphene won't help and TRT is the appropriate route.

Does enclomiphene actually work? What the evidence shows

The clinical case for enclomiphene rests on a small but consistent body of randomized trials, mostly from the drug's development program:

• In a randomized study of obese hypogonadal men, oral enclomiphene raised testosterone into the normal range while preserving sperm concentration, whereas topical testosterone raised testosterone but suppressed sperm counts — the authors framed it as "restoration instead of replacement." Kim ED et al., BJU International, 2016.
• An earlier randomized phase II trial similarly found enclomiphene citrate increased testosterone while maintaining sperm output, in contrast to topical testosterone gel. Wiehle RD et al., Fertility & Sterility, 2014.
• A pharmacology review concluded enclomiphene is an effective option for secondary hypogonadism specifically, and highlighted the fertility advantage over exogenous testosterone while noting the need for longer-term data. Rodriguez KM, Pastuszak AW, Lipshultz LI, Expert Opinion on Pharmacotherapy, 2016.

The honest read: the mechanism is well supported and the fertility-preserving effect is real and replicated. What's missing is what would let it fully rival TRT — large, long-duration trials measuring hard outcomes (cardiovascular events, prostate safety, bone density) over years, not months. You can browse the underlying literature via PubMed.

Is enclomiphene FDA-approved? The compounding reality

No. Despite the trial record, there is no FDA-approved enclomiphene product for treating low testosterone in the U.S. The branded candidate, Androxal (Repros Therapeutics), reached late-stage trials in the mid-2010s but did not gain FDA approval, and the company was ultimately dissolved. As a result, every enclomiphene prescription written today is off-label and filled by a compounding pharmacy.

This is legal and common, but it has consequences worth understanding. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or manufacturing quality the way approved drugs are, so potency and consistency can vary by pharmacy. Insurance almost never covers compounded enclomiphene, which is why telehealth clinics sell it as a cash-pay subscription. When a provider markets enclomiphene, "FDA-registered pharmacy" or "LegitScript-certified" refers to the dispensing pharmacy — not to FDA approval of the drug for this use. There is no such approval to point to.

Who is enclomiphene for — and who is it not for?

Which telehealth providers prescribe enclomiphene?

The providers below list enclomiphene in their formulary, ordered by our methodology score (never by who pays us). Maximusis the brand most associated with enclomiphene — its founder popularized the "Oral TRT+" framing — though it scores lower on our rubric for fulfillment and pricing-transparency reasons detailed in its review. Hone Healthlists the cheapest published enclomiphene price in this set. Each provider's Transparency Grade is shown so you know how much they disclose before intake.

Other platforms not on our scored list — including Hims, which sells compounded enclomiphene as prepaid plans — also offer it [Reported]. Compare the full men's wing on the TRT rankings.

The honest risks and unknowns

• Compounding variability. Without FDA manufacturing oversight, dose consistency depends on the pharmacy. Ask which pharmacy fills it and whether they test potency.
• Estradiol rises too. Because enclomiphene increases the whole signaling cascade, estradiol can climb alongside testosterone — a reason monitoring bloodwork matters, and a plausible driver of libido or mood side effects.
• Paradoxical sexual side effects. Some men report reduced libido or erectile issues, particularly at higher doses — counterintuitive for a testosterone raiser, and reported across community forums as well as trials.
• Thinner long-term data.Testosterone has decades of cardiovascular, prostate, and bone data. Enclomiphene does not. Treat any "safer than TRT" marketing claim as unproven on hard long-term outcomes.
• Not a shortcut or an enhancer. Enclomiphene treats diagnosed hypogonadism; using it to push an already-normal testosterone higher is off-label, under-studied, and not what the trials tested.

Frequently asked questions